Dyne Therapeutics (NASDAQ:DYN) Shares Down 3.7% - What's Next?

Key Points

• Dyne Therapeutics' stock decreased by 3.7% during trading, closing at $12.80, with trading volume dropping to 235,663 shares, significantly lower than its average daily volume.
• Several analysts have downgraded Dyne Therapeutics, including JPMorgan lowering its target price from $10.00 to $9.00, while Guggenheim maintains a "buy" rating with a $50 target price.
• Dyne Therapeutics disclosed a $0.97 EPS for the previous quarter, beating estimates, while the consensus forecast for the current year EPS stands at -3.44.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) dropped 3.7% during trading on Thursday . The stock traded as low as $12.87 and last traded at $12.80. Approximately 235,663 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 2,603,448 shares. The stock had previously closed at $13.28.

Analyst Upgrades and Downgrades

DYN has been the subject of a number of research reports. JPMorgan Chase & Co. cut their target price on shares of Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating for the company in a research report on Tuesday, July 15th. Robert W. Baird decreased their target price on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating for the company in a research note on Wednesday, June 18th. Sanford C. Bernstein initiated coverage on shares of Dyne Therapeutics in a report on Tuesday, June 24th. They set a "market perform" rating and a $13.00 target price on the stock. Stifel Nicolaus decreased their target price on shares of Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating for the company in a research report on Thursday, July 31st. Finally, Guggenheim reiterated a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, June 18th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Dyne Therapeutics has an average rating of "Buy" and an average target price of $34.07.

Dyne Therapeutics Trading Down 0.3%

The company has a debt-to-equity ratio of 0.17, a quick ratio of 16.83 and a current ratio of 16.83. The business has a 50-day simple moving average of $11.04 and a two-hundred day simple moving average of $11.15. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of -3.43 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Monday, July 28th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.02. As a group, research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Activity at Dyne Therapeutics

In other news, CEO John Cox sold 2,640 shares of the stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $13.41, for a total value of $35,402.40. Following the completion of the sale, the chief executive officer owned 199,539 shares of the company's stock, valued at approximately $2,675,817.99. This represents a 1.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 14.14% of the company's stock.

Institutional Trading of Dyne Therapeutics

Several hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. lifted its holdings in Dyne Therapeutics by 11.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company's stock worth $91,000 after buying an additional 955 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Dyne Therapeutics by 5.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company's stock worth $237,000 after purchasing an additional 1,115 shares during the period. Arizona State Retirement System grew its stake in Dyne Therapeutics by 9.2% during the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock valued at $183,000 after purchasing an additional 1,481 shares during the last quarter. Caxton Associates LLP grew its stake in Dyne Therapeutics by 10.9% during the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company's stock valued at $158,000 after purchasing an additional 1,627 shares during the last quarter. Finally, CWM LLC grew its stake in Dyne Therapeutics by 168.1% during the 2nd quarter. CWM LLC now owns 3,030 shares of the company's stock valued at $29,000 after purchasing an additional 1,900 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.